Displaying 1 - 2 of 2
| Active Ingredient | ZIDOVUDINE |
| Therapeutic Class | NRTI |
| Indications | In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, la More ... |
| Caution | Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincrist More ... |
| Dose Range | Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LAMIVUDINE | ZIDOVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | Indicated in combination with other antiretroviral agents for the treatment of HIV infection. |
| Caution | Headache, fatigue, nausea, vomiting, diarrhoea, neutropenia, anemia, neuropathy , insomnia, nasal symptoms and musculoskeletal pain. |
| Dose Range | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine per tablet). Not recommended in children under 12 y ears. |
| Drug Interactions | |
| Pregnancy | The incidence and clinical significance of mitochondrial dysfunction after in ut More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |